Victoria Socha

DocwireNews

Patients with hyperkalemia may be treated with the potassium binder sodium zirconium cyclosilicate (SZC), a nonabsorbed nonpolymer zirconium silicate. Results of previous studies have shown that patients with hyperkalemia treated with SCZ have a higher rate of continuation of renin-angiotensin-aldosterone system (RAAS) inhibitors. However, according to Wakana Kimura, MD, and colleagues, there have been no studies on the effect of SCZ on continuation of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) in patients with hyperkalemia, compared with that of calcium polystyrene sulfonate (CPS). Results were reported in the Journal of Nephrology.The researchers conducted a single-center, retrospective observational study that enrolled patients on ACE inhibitors or ARBs who were newly prescribed SCZ or CPS at a tertiary referral hospital between August 2020 and April 2022. The primary outcome measure was prescription for a ACE inhibitor or ARB 3 months following initiation of a potassium binder.The total cohort included 174 patients on ACE inhibitor or ARB who were newly administered SCZ (n=62) or CPS (n=112). At 3 months following initiation of a potassium binder, the prescription rate of an ACE inhibitor or ARB was significantly higher in the SCZ group than in the CPS group (89% vs 72%, respectively).In multivariable logistic regression models, there was am independent association between SCZ and the primary outcome of ACE inhibitor or ARB prescription (odds ratio, 2.66; 95% CI, 1.05-7.43). There was also a significant association between SCZ and the primary outcome in the propensity score-matched comparison.In conclusion, the authors said, &ldquo;Our study suggests that administering SCZ to patients with hyperkalemia allows for a higher continuation rate of ACE inhibitors or ARBs than CPS. These findings suggest that SCZ had potential benefits for patients with chronic kidney disease receiving RAAS inhibitors.&rdquo;Source: <a href="https://link.springer.com/article/10.1007/s40620-023-01743-4">Journal of Nephrology</a>

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Managing Hyperkalemia With Sodium Zirconium Cyclosilicate

Hyperkalemia

Patients with hyperkalemia may be treated with the potassium binder sodium zirconium cyclosilicate (SZC), a nonabsorbed nonpolymer zirconium silicate.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe